This page brings together all of the site's tools and resources for physicians: clinical calculators, systemic treatment regimens with doses and monitoring, specialist lessons and pre-treatment checklists. Every formula and dose is referenced to the original study or an authoritative guideline.
Pre-treatment checklist
35 tools and calculators
Carboplatin dose, body surface area, clearance, MASCC, Khorana, IPI, R2-ISS, ELN 2022, RECIST and more. All tools
62 treatment regimens
FOLFOX, FLOT, AC-T, TCHP, R-CHOP, VRd, 7+3 and more, with premedication, monitoring and dose modification. All regimens
32 specialist lessons
From febrile neutropenia to cardio-oncology and pharmacogenomics. All lessons
Study library
Summaries of key trials and guidelines. Study library
Tools and calculators
Drug dosing and kidney function
Fever, neutropenia and treatment complications
- ANC calculator (absolute neutrophil count)
- MASCC score in febrile neutropenia
- CISNE score in clinically stable febrile neutropenia
- G-CSF prophylaxis: is it needed?
- Preventing chemotherapy-induced nausea: choosing the antiemetic regimen
- Tumour lysis syndrome: Cairo-Bishop criteria and prevention
- Corrected calcium and hypercalcaemia of malignancy
- QTc calculator (Fridericia and Bazett) for anticancer drugs
Assessing the patient before treatment
Prognosis and risk stratification in haematological malignancies
- IPI, R-IPI, NCCN-IPI and CNS-IPI calculator in DLBCL
- Follicular Lymphoma International Prognostic Index (FLIPI)
- International Prognostic Score for advanced Hodgkin lymphoma (IPS)
- Mantle Cell Lymphoma International Prognostic Index (MIPI)
- CLL-IPI prognostic index
- ELTS and Sokal scores in chronic myeloid leukaemia (CML)
- Myeloma staging: ISS, R-ISS and R2-ISS
- IPSS-R in myelodysplastic syndrome (MDS)
- ELN 2022 genetic risk classification of AML
Pain and supportive care
Treatment planning
Solid tumours and screening
Evidence and studies
Systemic treatment regimens
Colorectal cancer
Pancreatic cancer
Gastric cancer
Oesophageal cancer
Liver cancer
Breast cancer
- AC followed by paclitaxel (dose-dense and weekly)
- TC regimen (docetaxel and cyclophosphamide): dose and schedule
- TCHP regimen: dose and schedule in HER2-positive breast cancer
- Weekly paclitaxel with trastuzumab (APT regimen)
- KEYNOTE-522 regimen: pembrolizumab and chemotherapy in triple-negative breast cancer
- Trastuzumab emtansine (T-DM1, Kadcyla): dose and schedule
- Trastuzumab deruxtecan (T-DXd, Enhertu): dose and monitoring
- Adjuvant capecitabine after neoadjuvant treatment (CREATE-X)
- Sacituzumab govitecan (Trodelvy)
- Pembrolizumab with chemotherapy in metastatic triple-negative breast cancer (KEYNOTE-355)
Lung cancer
- Carboplatin, pemetrexed and pembrolizumab (KEYNOTE-189)
- Carboplatin, paclitaxel and pembrolizumab (KEYNOTE-407)
- Carboplatin-etoposide with atezolizumab or durvalumab in small cell lung cancer
- Durvalumab after chemoradiotherapy in stage 3 lung cancer (PACIFIC)
- Pembrolizumab alone in lung cancer with high PD-L1 (KEYNOTE-024)
- Osimertinib with pemetrexed and platinum (FLAURA2)
- Amivantamab with lazertinib (MARIPOSA)
- Adjuvant alectinib after surgery for ALK-positive lung cancer (ALINA)
Germ cell (testicular) tumours
Bladder cancer
Prostate cancer
Kidney cancer
Ovarian cancer
Cervical cancer
Endometrial cancer
Head and neck cancers
Lymphoma
Multiple myeloma
Leukaemia
Brain tumours
Melanoma
Sarcoma
Specialist lessons
- Molecular tests and biomarkers needed before treatment, by cancer
- Indications for haematopoietic stem cell transplantation, donor selection and the conditioning regimen
- Graft-versus-host disease (GVHD): prophylaxis, grading and treatment
- 15 things to stop doing in cancer treatment
- DPYD, UGT1A1 and TPMT/NUDT15 testing before chemotherapy
- Hepatitis B and chemotherapy: screening and prevention of reactivation
- Febrile neutropenia: assessment, empirical antibiotics and outpatient treatment
- 10 cheap steps that save patients' lives
- Infection prevention and vaccination in cancer patients
- Chemotherapy extravasation: prevention and management
- Infusion and hypersensitivity reactions to anticancer drugs: management, rechallenge and desensitisation
- Cardiac monitoring during cancer treatment (cardio-oncology)
- Bone-modifying agents in cancer: bone metastases, adjuvant use and osteonecrosis of the jaw
- Anticancer drug dose adjustment in renal and hepatic impairment
- Anaemia in cancer: transfusion, erythropoiesis-stimulating agents and iron
- Germline genetic testing in cancer: who, and which genes?
- Geriatric assessment before chemotherapy
- Early palliative care in advanced cancer
- Management of brain metastases
- Cancer of unknown primary (CUP)
- Fertility preservation before cancer treatment
- Assessing tumour response: RECIST 1.1, iRECIST and the Lugano criteria
- Oncological emergencies: from febrile neutropenia to spinal cord compression
- CTCAE version 5 adverse event grading: quick reference
- Acute myeloid leukaemia (AML): 2022 classification, ELN genetic risk and treatment
- Immunotherapy toxicity: checkpoint inhibitors, CAR-T and bispecific antibodies
- Myelodysplastic syndrome (MDS): the 2022 classifications, IPSS-R and IPSS-M, and risk-adapted treatment
- Cancer cachexia: assessment and management
- Venous thromboembolism in cancer: risk assessment, prevention and treatment
- Critical reading of oncology trials and interpreting biomarkers
- Malignant pleural effusion: drainage, pleurodesis or an indwelling catheter
- Cancer during pregnancy: chemotherapy and decisions
This page is based on reputable scientific sources and was last updated on 28 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.
Printed from the website; the full and up-to-date version: https://drdabiri.com/en/for-doctors/